V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Merus Executive Compensation (FY24)

MRUS · Executive and director compensation, fiscal 2022 to 2024
Chief executive, fiscal 2024
◇
Sven (Bill) Ante Lundberg
Latest say-on-pay support
=
May 7, 2024
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in one industry, with dashboards, peer screens and board-ready briefs. Three seats, one year.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Merus

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 19, 2026Latest filing (DEF 14A): April 24, 2025
6 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Merus brief$1,500Get the executive brief
Velarion Member, one year
165 figures on this page: 162 cited to the filing that reported them, 3 calculated from figures it prints. See the citations

More on Merus

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Sven (Bill) Ante Lundberg: $4,671,327 → $9,643,774 (106.4% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Merus' chief executive and what were they paid?
Sven (Bill) Ante Lundberg was paid $9,643,774 in total compensation as President, Chief Executive Officer for fiscal 2024. Lundberg's total was 106.4% higher than the $4,671,327 reported for fiscal 2023.
What was Merus' say-on-pay result?
Shareholders recorded 99.6% support for the say-on-pay proposal at the meeting held May 7, 2024 for fiscal 2023.
Which companies are in Merus' peer group?
The disclosed peer group names Arcus Biosciences, Inc., Arrowhead Pharmaceuticals, Inc., Arvinas, Inc., Biohaven Ltd. and Celldex Therapeutics, Inc., among others.
What is Merus' chief executive pay ratio?
The company reported a chief executive pay ratio of 47:1 for fiscal 2024, against median employee compensation of $204,923.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Sven (Bill) Ante Lundberg
President, Chief Executive Officer
◇◇—◇◇—◇— not reconciled
Andrew Joe
Former Chief Medical Officer
◇◇—◇◇——◇
Peter Silverman
Chief Operating Officer and General Counsel
◇——◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Greg Perry
Chief Financial Officer
◇——◇◇—◇◇
Sven (Bill) Ante Lundberg
President, Chief Executive Officer
◇◇—◇◇—◇◇
Peter Silverman
Chief Operating Officer and General Counsel
◇——◇◇—◇◇
Andrew Joe
Former Chief Medical Officer
◇——◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Sven (Bill) Ante Lundberg
President, Chief Executive Officer
◇——◇◇—◇◇
Fabian Zohren
Chief Medical Officer
◇——◇◇—◇◇
Peter Silverman
Chief Operating Officer and General Counsel
◇——◇◇—◇◇
Greg Perry
Chief Financial Officer
◇——◇◇—◇◇
Andrew Joe
Former Chief Medical Officer
Departed during or after this year
◇——◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Andrew JoeOPTION◇——◇—◇◇
Fabian ZohrenOPTION◇——◇—◇◇
Greg PerryOPTION◇——◇—◇◇
Peter SilvermanOPTION◇——◇—◇◇
Sven Ante LundbergOPTION◇——◇—◇◇
Fiscal 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Greg PerryRSU◇◇——
RSU◇◇——
Option◇—◇5/8/2034
Sven (Bill) Ante LundbergOption◇—◇1/1/2031
Option◇—◇1/1/2032
Option◇—◇5/8/2034
Option◇—◇2/2/2033
Option◇—◇5/8/2034
Peter SilvermanOption◇—◇1/1/2031
Option◇—◇2/2/2033
Option◇—◇5/8/2034
Option◇—◇1/1/2032
Option◇—◇1/4/2033
Fabian ZohrenOption◇—◇7/1/2034
Andrew JoeOption◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Fabian Zohren
Chief Medical Officer · Employment agreement
Severance multiple◇
Greg Perry
Chief Financial Officer · Employment agreement
Severance multiple◇
Peter Silverman
Chief Operating Officer and General Counsel · Employment agreement
Severance multiple◇
Sven (Bill) Ante Lundberg
President, Chief Executive Officer · Employment agreement
Severance multiple◇

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jason Haddock
◇—◇———◇
Anand Mehra
◇—◇———◇
Victor Sandor
◇—◇——◇◇
Mark Iwicki
◇—◇———◇
Paolo Pucci
◇—◇———◇
Maxine Gowen
◇—◇———◇
Len Kanavy
◇—◇———◇
Sven (Bill) Ante Lundberg served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • Arcus Biosciences, Inc. RCUS
  • Arrowhead Pharmaceuticals, Inc. ARWR
  • Arvinas, Inc. ARVN
  • Biohaven Ltd. BHVN
  • Celldex Therapeutics, Inc. CLDX
  • Crinetics Pharmaceuticals, Inc. CRNX
  • Cytokinetics, Inc. CYTK
  • IDEAYA Biosciences, Inc. IDYA
  • ImmunityBio, Inc. IBRX
  • Immunovant, Inc. IMVT
  • Iovance Biotherapeutics, Inc. IOVA
  • Krystal Biotech, Inc. KRYS
  • Madrigal Pharmaceuticals Inc. MDGL
  • Recursion Pharmaceuticals, Inc. RXRX
  • Revolution Medicines, Inc. RVMD
  • SpringWorks Therapeutics, Inc. SWTX
  • Syndax Pharmaceuticals, Inc. SNDX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2023May 7, 2024=◇◇◇
2022May 26, 2023=◇◇◇
2021May 31, 2022=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Sven (Bill) Ante Lundberg (President, Chief Executive Officer), FY2024 total compensation $9,643,774 (base salary $676,000) [exec_comp, SEC accession 0001193125-25-093505, filed 2025-04-24]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Tell me when Merus files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Merus disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Merus sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Merus' disclosed peer group is defensible, who names Merus back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
165 figures on this page: 162 cited to the filing that reported them, 3 calculated from figures it prints.
162 cited to the filing
3 calculated from the filing

Documents cited

  1. 0001193125-25-093505
    2024 DIRECTOR COMPENSATION TABLE · 2024 SUMMARY COMPENSATION TABLE · 2024 Summary Compensation Table · CEO Pay Ratio · and 4 more sections
  2. 0001193125-24-133796
  3. 0001193125-24-091402
    2023 Summary Compensation Table · Summary Compensation Table
  4. 0001193125-23-156007
  5. 0001193125-23-126896
    Summary Compensation Table
  6. 0001193125-22-164095
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Merus executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/MRUS (accessed 2026).
Short form: data: Velarion

The paid brief for Merus

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
6 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Merus and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Merus discloses

The companies named in MRUS's own disclosed peer group.

Arcus Biosciences, Inc.Arrowhead Pharmaceuticals, Inc.Arvinas, Inc.Biohaven Ltd.Celldex Therapeutics, Inc.Crinetics Pharmaceuticals, Inc.Cytokinetics, Inc.IDEAYA Biosciences, Inc.ImmunityBio, Inc.Immunovant, Inc.Iovance Biotherapeutics, Inc.Krystal Biotech, Inc.Madrigal Pharmaceuticals Inc.Recursion Pharmaceuticals, Inc.Revolution Medicines, Inc.SpringWorks Therapeutics, Inc.Syndax Pharmaceuticals, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy